Vertex Has "Significant Financial Firepower"

Vertex Pharmaceuticals (NASDAQ: VRTX) continued its dominance in cystic fibrosis (CF) in the second quarter, increasing sales as it waits for approval of the next CF cocktail that's under Food and Drug Administration review.

The revenue helped Vertex increase its rainy day fund to $4 billion, up from $3.2 billion at the end of last year.

Metric

Continue reading

Quelle Fool.com